Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Exiqon, Oncotech, Merck deal

EXQ will acquire Oncotech for 6.2 million shares valued at DKK225.7 million ($44.9 million) based on EXQ's close

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE